Drug Type AAV based gene therapy |
Synonyms Neurotrophin 3 gene therapy, NT 3 gene therapy |
Target |
Action- |
Mechanism Neurotrophin-3 expression stimulants, Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Charcot-Marie-Tooth Disease, Type Ia | Phase 2 | United States | 01 Apr 2027 |